<DOC>
	<DOCNO>NCT01321437</DOCNO>
	<brief_summary>The purpose research study determine efficacy Axitinib treating individual Stage III melanoma .</brief_summary>
	<brief_title>Study Anti-Angiogenesis Agent Axitinib Patients With Stage III Malignant Melanoma</brief_title>
	<detailed_description>The American Cancer Society estimate 68,720 new case melanoma ( 29,900 men 25,200 woman ) annually United States , 8,650 people die cancer . The systemic therapy advance disease remain palliative new agent find might improve survival patient stage III melanoma . Melanomas often vascular , decrease number blood vessel supply tumor may starve needed nutrient . An approach block growth blood vessel supply tumor inhibit vascular endothelial growth factor receptor tyrosine kinase ( VEGFR TK ) signal pathway . Axitinib ( AG 013736 ) VEGFR TK inhibitor . Because poor prognosis patient stage III melanoma indication anti-angiogenesis compound might clinically meaningful activity disease , Phase 2 trial vascular endothelial growth factor receptor tyrosine kinase ( VEGFR TK ) inhibitor Axitinib ( AG 013736 ) warrant .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Histologically document melanoma local lymph node stage III metastases . No prior systemic therapy . Prior adjuvant therapy interferon count . No expectation effect prior anticancer therapy . At least 1 target lesion , define RECIST , irradiate . New lesion develop previously irradiate field may use site measurable disease assume criterion meet . All target lesion must unidimensional diameter least 1 cm spiral CT scan reconstruction algorithm 0.5 cm ) , standard uptake value ( SUV ) value ≥ 2.5 . Baseline measurements/evaluations must complete within 4 week prior treatment . Adequate bone marrow , hepatic , renal function document within 14 day prior treatment document : absolute neutrophil count ( ANC , calculate absolute number neutrophil band ) ≥1.5 x 10^9 cells/L platelet ≥100 x 10^9 cell /L aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 x upper limit normal ( ULN ) , unless liver metastasis case AST ALT ≤5.0 x ULN total bilirubin ≤1.5 x ULN serum creatinine ≤1.5 x ULN calculate creatinine clearance ≥60 mL/min urinary protein &lt; 2+ urine dipstick . If dipstick ≥2+ 24hour urine collection do patient may enter urinary protein &lt; 2 g per 24 hour Age ≥18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 No evidence preexist uncontrolled hypertension document 2 baseline blood pressure read take least 1 hour apart . The baseline systolic blood pressure reading must ≤140 , baseline diastolic blood pressure reading must ≤90 . Patients whose hypertension control antihypertensive therapy eligible . Women childbearing potential must negative serum urine pregnancy test within 7 day prior treatment . Written voluntary inform consent Stage IV disease History hemoptysis Gastrointestinal abnormality include : inability take oral medication requirement intravenous alimentation prior surgical procedure affect absorption include gastric resection treatment active peptic ulcer disease past 6 month active gastrointestinal bleeding , unrelated cancer , evidence hematemesis , hematochezia melena past 3 month without evidence resolution document endoscopy colonoscopy . malabsorption syndrome . Previous treatment antiangiogenesis agent include thalidomide , inhibitor epidermoid growth factor ( EGF ) , platelet derive growth factor ( PDGF ) , fibroblast growth factor ( FGF ) receptor . Current use anticipate inability avoid use drug know potent cytochrome P450 3A4 ( CYP3A4 ) inhibitor ( ie , grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , erythromycin , clarithromycin , ergot derivative , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , delavirdine ) . Current use anticipate inability avoid use drug know CYP3A4 Cytochrome P450 1A2 ( CYP1A2 ) inducer ( ie , carbamazepine , dexamethasone , felbamate , omeprazole , phenobarbital , phenytoin , primidone , rifabutin , rifampin , St. John 's wort ) . Active seizure disorder evidence brain metastasis . ( Appropriate image do rule brain metastasis . ) A serious uncontrolled medical disorder active infection would impair ability receive study treatment . History malignancy ( melanoma ) except treat curative intent skin cancer ( melanoma ) situ breast cervical cancer treat curative intent cancer evidence disease 5 year . 10 . Major surgical procedure radiation therapy within 4 week treatment , minimum rest period 28 day post surgery ; maximum rest period 56 day post surgery . Dementia significantly alter mental status would prohibit understanding rendering informed consent compliance requirement protocol . Patients ( male female ) procreative potential use adequate contraception practice abstinence . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Axitinib</keyword>
	<keyword>Anti-angiogenesis</keyword>
	<keyword>Neoadjuvant Melanoma</keyword>
</DOC>